Anna Barry, MS
Creating and validating DICER knockout HCC cell lines using CRISPR/Cas9 technology for future studies. These models will be used in the integrative functional genomics studies focusing on AGO2 as a possible oncogenic RBP.
Rajkumar Baldeosingh, MS
Investigating the nuclear role of NELFE in modifying chromatin-dependent gene expression of MYC target genes in HCC. The goal of this project is to understand the molecular mechanism which affects more than 30% of HCC tumors.
Kai Zhang, PhD
Using CRISPR/Cas9 technology to develop a NELFE-GFP knock in model in HCC cell lines. He is focused on the dynamic role of NELFE in the cell, and how it regulates its RNA targets through the various sequence characteristics of the target RNAs. He is also involved with preparing genome wide CIRSPR/Cas9 screens to advance the precision medicine approach to treating specific HCC subtypes, specifically the 20-NELFE dependent MYC (NDMPOS) gene signature.